Kairos Pharma Ltd. (NYSE American: KAPA) announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer's XOFIGO (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. This partnership targets a significant unmet need in advanced prostate cancer, where bone metastases are common and often lead to poor outcomes.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. The company previously reported interim Phase 2 data showing median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population. The collaboration aims to determine whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy.
Kairos said preclinical studies have demonstrated ENV-105's ability to re-sensitize tumors to radiation. Management believes that combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer. The announcement underscores the potential of ENV-105 to address drug resistance, a major challenge in oncology.
For more details, the full press release can be accessed at https://ibn.fm/emSc4.
Kairos Pharma, based in Los Angeles, California, focuses on oncology therapeutics, using structural biology to overcome drug resistance and immune suppression. ENV-105 targets CD105, a key driver of resistance and disease relapse. The company is also evaluating ENV-105 in a Phase 1 trial for non-small cell lung cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the FDA or any other foreign regulator.
This collaboration highlights the growing interest in combination therapies for hard-to-treat cancers. If successful, the ENV-105 and XOFIGO combination could offer new hope for patients with mCRPC, potentially improving survival and quality of life. The partnership also positions Kairos Pharma as a key player in the development of innovative cancer treatments.
